Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update

Can J Diabetes. 2015 Aug;39(4):250-2. doi: 10.1016/j.jcjd.2015.05.009.
No abstract available

Publication types

  • Review

MeSH terms

  • Canada / epidemiology
  • Canagliflozin / pharmacology
  • Canagliflozin / therapeutic use
  • Consensus*
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Disease Management*
  • Health Policy*
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Practice Guidelines as Topic / standards*
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors

Substances

  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin